Effects of the Consumption of a Supplement Rich in Docosahexaenoic Acid (DHA) From Algae
"Diseño y Validación en Humanos de un Nuevo Complemento Alimenticio Rico en Ácido Docosahexaenoico (DHA) Procedente de Algas"
1 other identifier
interventional
102
1 country
1
Brief Summary
Vegetarian diets are increasing worldwide. To prevent nutritional deficiencies, supplementation with nutrients that are only present in animal food can be needed. In relation to fatty acids, vegetarian diets involve low intake of omega-3 polyunsaturated fatty acids (n-3 PUFA) and low blood levels of the long-chain n-3 derivatives, whose main dietary sources are fish and shellfish, particularly the levels of docosahexaenoic acid (DHA), which has important health benefits, are low. In this regard, validation of supplements rich in the n-3 fatty acid DHA that are not obtained from fish is needed, thus the study will test the bioavailability and metabolic effects of a DHA supplement form algae. The study will be conducted on the effects of the DHA supplement versus placebo in vegetarian and non-vegetarian healthy adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 18, 2020
CompletedFirst Posted
Study publicly available on registry
February 20, 2020
CompletedStudy Start
First participant enrolled
March 10, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 5, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 5, 2021
CompletedJanuary 17, 2023
January 1, 2023
1.3 years
February 18, 2020
January 13, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Serum DHA
Docosahexanoic acid concentration in serum
Baseline
Serum DHA
Docosahexanoic acid concentration in serum
week 6
Serum DHA
Docosahexanoic acid concentration in serum
week 12
Serum DHA
Docosahexanoic acid concentration in serum
week 18
Study Arms (2)
DHA supplement
ACTIVE COMPARATORSupplement rich in DHA form algae source
Placebo
PLACEBO COMPARATORPlacebo supplement
Interventions
Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
Eligibility Criteria
You may qualify if:
- Adult (age ≥18 and ≤45 years).
- Healthy.
- Women.
- Men.
- Participant following either a vegetarian diet during at least 6 months or following a omnivorous diet but consuming fish 2 times per week or less.
You may not qualify if:
- Age \<18 and \>45 years old.
- Pregnancy.
- Diseases: liver diseases, gastric diseases, irritable bowel, hypercholesterolemia, hypertension, diabetes, biliary colic.
- Having participated in a clinical study in the last 3 months.
- Eating disorders.
- Consumption of foods fortified with omega-3 fatty acids in the last 3 months.
- Consumption of supplements of omega-3 fatty acids in the last 3 months.
- Participant who have followed either a vegetarian diet for less than six months or an omnivorous diet including fish more than 2 times per week.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Research Council, Spainlead
- Comunidad de Madridcollaborator
Study Sites (1)
M.Pilar Vaquero
Madrid, 28040, Spain
Related Publications (1)
Garcia-Maldonado E, Alcorta A, Zapatera B, Vaquero MP. Changes in fatty acid levels after consumption of a novel docosahexaenoic supplement from algae: a crossover randomized controlled trial in omnivorous, lacto-ovo vegetarians and vegans. Eur J Nutr. 2023 Jun;62(4):1691-1705. doi: 10.1007/s00394-022-03050-3. Epub 2022 Nov 23.
PMID: 36418565RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
M.Pilar Vaquero, Dr
CSIC
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
February 18, 2020
First Posted
February 20, 2020
Study Start
March 10, 2020
Primary Completion
July 5, 2021
Study Completion
July 5, 2021
Last Updated
January 17, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will not share